Form 8-K - Current report:
SEC Accession No. 0001213900-24-064718
Filing Date
2024-08-02
Accepted
2024-08-02 16:00:36
Documents
15
Period of Report
2024-08-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0210504-8k_inmune.htm   iXBRL 8-K 24260
2 PRESS RELEASE OF INMUNE BIO INC., DATED AUGUST 1, 2024 ea021050401ex99-1_inmune.htm EX-99.1 99626
3 GRAPHIC ex99-1_001.jpg GRAPHIC 11035
  Complete submission text file 0001213900-24-064718.txt   328653

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inmb-20240801.xsd EX-101.SCH 3018
5 XBRL LABEL FILE inmb-20240801_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE inmb-20240801_pre.xml EX-101.PRE 22361
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0210504-8k_inmune_htm.xml XML 3792
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 241170825
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)